With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.